Hemab Therapeutics Holdings Inc. Company Profile
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Hemab Therapeutics at a glance
Hemab Therapeutics Holdings Inc. (NASDAQ: COAG) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Hemab Therapeutics is led by Dr. Benny Sorensen M.D., Ph.D. and employs about 59 people. The company's shares have traded publicly since 2026.
At a market capitalization of $1.44 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002114044, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Hemab Therapeutics do?
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Hemab Therapeutics Holdings Inc.
- Ticker
- NASDAQ: COAG
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Benny Sorensen M.D., Ph.D.
- Employees
- 59
- Headquarters
- 101 Main Street, Cambridge, MA, United States
- Phone
- (617) 553-3952
- Website
- hemab.com
- IPO year
- 2026
- Market cap
- $1.44B
- SEC CIK
- 0002114044
Companies similar to Hemab Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MAZEMaze Therapeutics Inc. | 25.88 | -1.41% | $1.44B | vs COAG |
| IMCRImmunocore Holdings plc ADR | 29.09 | -1.09% | $1.50B | vs COAG |
| INBXInhibrx Biosciences Inc. | 92.76 | -0.64% | $1.37B | vs COAG |
| REPLReplimune Group Inc. | 13.04 | -1.21% | $1.23B | vs COAG |
| VORVor Biopharma Inc. | 19.13 | +1.86% | $1.13B | vs COAG |
| IMTXImmatics N.V. | 7.37 | -1.07% | $1.12B | vs COAG |
| MESOMesoblast Limited ADR | 13.75 | -1.36% | $1.79B | vs COAG |
| NVAXNovavax Inc. | 11.01 | -1.87% | $1.82B | vs COAG |